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tionship, is now being dramatically affected by shifts in the collective human microbiome re-
sulting from changes in the environment and societal norms. Resulting perturbations of
intestinal host-microbe interactions can lead to miscues and altered host responses that in-
crease the risk of pathogenic processes and promote “western” disorders such as inflammatory
bowel diseases, cancers, obesity, diabetes, autism, and asthma. Given the current challenges
and limitations in gene therapy, approaches that can reshape the gut microbiome represent a
reasonable strategy for restoring the balance between host and microbes. In this review and
commentary, we highlight recent progress in our understanding of the intestinal microbiome
in the context of health and diseases, focusing on mechanistic concepts that underlie the com-
plex relationships between host and microbes. Despite these gains, many challenges lie ahead
that make it difficult to close the gap between the basic sciences and clinical application. We
will discuss the potential therapeutic strategies that can be used to manipulate the gut micro-
biota, recognizing that the promise of pharmabiotics (“bugs to drugs”) is unlikely to be
completely fulfilled without a greater understanding of enteric microbiota and its impact on
mammalian physiology. By leveraging the knowledge gained through these studies, we will
be prepared to enter the era of personalized medicine where clinical inventions can be
custom-tailored to individual patients to achieve better outcomes.
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Gut microbiota and human diseases 133Introduction
Through co-evolution, hosts and microbes have forged a
mutually beneficial or tolerant relationship, which is man-
ifested in virtually all life forms. In humans and mammals,
the acquisition of gut microbes does not occur randomly
and is highly dependent on host factors, environmental
cues, and self-assembly rules exert by microbes them-
selves. Once fully developed, the gut microbiome becomes
an “essential” acquired organ that provides many vital
functions to the host. However, the fundamental nature
and stability of this evolutionarily determined relationship
between host and microbe is now being threatened by
drastic changes in the environment, diet, and life style over
the past 50e100 years which have almost certainly resha-
ped the collective human gut microbiome. Corresponding
and adaptive changes in the collective human genome, on
the other hand, cannot proceed with such rapidity.
Resulting mismatches in host-microbe relationships can
then lead to homeostatic chaos, possibly explaining the
increased incidence and prevalence of many disorders that
have merged with alarming frequency in the modern age.
In this review and commentary, we highlight recent
progress in understanding host-microbe interactions in the
context of health and disease. In doing so, we provide
specific examples where mechanistic insights into host-
microbe relationships have transformed our conceptual
thinking in this area. At the same time, we also bring up the
many limitations and daunting challenges ahead of us that
must be overcome to move the field forward. With the era
of personalized medicine upon us, new knowledge will
create opportunities to maintain health, effectively treat
illness, and achieve better clinical outcomes.
The microbial organ: acquire and essential for
health
The human gut microbiome is dominated by four phyla:
Firmicutes, Bacteroidetes, Proteobacteria, and Actino-
bacteria. Firmicutes and Bacteroidetes are generally the
most abundant of the gut microbiota, followed by Proteo-
bacteria and Actinobacteria, with minor contributors,
including Verrucomicrobia and Fusobacteria.1 Bacteroides
and Ruminococcus are consistent with enriched intake of
animal sources, while a plant-based diet favors Prevotella.2
The ratio of Prevotella to Bacteroides constitutes a
potentially useful index for clinical diagnosis. Butyrate-
producing bacteria, including Clostridium groups IV (Fae-
calibacterium prausnitzii) and XIVa, Roseburia spp.,
Butyricicoccus, and lactic acid bacteria (LAB), mainly
Lactobacillus and Bifidobacterium, are believed to benefit
the host through anti-inflammatory, anti-tumorigenic, and
pathogen exclusion properties that they possess.3e5 There
are also interactions between lactic acid- and butyrate-
producing bacteria, which involve the ability of the latter
to feed on lactate.1 Dysbiosis caused by a variety of per-
turbations can increase the risk of disease directly or
indirectly when the delicate balance in bacterial commu-
nity and host and microbiota are perturbed.
As an acquired and essential organ of the body, the gut
microbiota provide a wide variety of beneficial functions,including: i) gleaning indigestible ingredients from food and
synthesizing nutritional factors, such as vitamins; ii)
detoxifying the deleterious xenobiotics and affecting the
host metabotypes; iii) development of a robust systemic
and intestinal immune system; vi) providing signals for
epithelial renewal and maintaining gut integrity; and iv)
secretion of anti-microbial products, which negatively
select against pathogenic bacteria through the develop-
ment of colonization resistance.6,7 These functions are
vital, because in the absence of gut microbiota or with its
ablation with broad spectrum antibiotics, significant con-
sequences can happen, e.g. improper development of the
gut immune system and the development of Clostridium
difficile antibiotic-associated colitis, respectively.
Gut microbial interactions are complex and fluid,
capable of adjusting to physiological perturbations that are
encountered on a daily basis. However, large or selective
shifts in the gut microbiota as a consequence of host
pathobiology, alterations of diet, medications, and other
environmental triggers can upset critical inter-microbe as
well as host-microbe relationships to initiate pathophysio-
logical processes leading to disease. Two examples of this
are the loss of beneficial microbes and their products and
the emergence of disease-promoting microbes that produce
microbial metabolites and proinflammatory mediators that
negatively impact the intestine and other organ systems.
Short-chain fatty acids (SCFA), such as acetate, butyrate
and propionate, are major fermentation products of mi-
croorganisms in gut. SCFA are the main energy source for
colonocytes that also provide a number of other beneficial
effects in maintaining intestinal homeostasis. For example,
butyrate-producing bacteria have recently gained attention
because they are important for a healthy colon and when
altered contribute to emerging diseases, such as IBD.8
Butyrate can be produced directly by certain groups of
bacteria: Butyricicoccus pullicaecorum; Faecalibacterium
prausnitzii, Rosebuia and indirectly by cross-feeding some
butyrate producers with lactate, as in the case of Eubac-
terium ballii, Anaerostipes caccae, and Escherichia coli.3
While butyrate is produced in colon, it can affect distal
organs. Human serum butyrate, for instance, is in the range
of 4 mM in British adults, and 29 mM in the hepatic portal
vein which brings fats and other nutrients from the diges-
tive tract to the liver.4 Shifts in butyrate-producing bacteria
caused by bioavailability of substrate or changes in gut
microbial membership and abundance can drastically
change the production and amount of SCFAs that is deliv-
ered to the gut and distal organs.
Gut microbiota also produce a host of other metabolites
that include many as yet unidentified or incompletely
characterized natural products,5 as well as compounds well
known to us. Among the latter are conjugated linoleic
acids, vitamins (e.g. folate, riboflavin), and secondary bile
acids, all having local and systemic effects.9 Conjugated
linoleic acid, derived from bacterial metabolism of dietary
linoleic acid, has many putative effects on host functions,
including being anti-inflammatory and in regulating meta-
bolic pathways.9 About 5% of secreted bile acid escape
reabsorption in the ileum and enter the colon, where,
because of their biophysical properties, they can dramati-
cally affect the microbial landscape by suppressing many
commensal gut microbes that are bile-intolerant while
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bile acids are rapidly converted to secondary bile acids
through 7-alpha dehydroxylation by bacteria. Secondary
bile acids (SBA) activate the nuclear farnesoid X receptor
(FXR) and thereby protect against muscle fat deposition.6
SBA lithocholic acid (LCA) also bind to the vitamin D re-
ceptor (VDR) to promote detoxifying mechanisms that
protect host cells against injury and inflammation.7,10,11 At
physiological levels, SBA may contribute to the regulation
of mucosal barrier function, cell renewal, and immune
function. At higher, non-physiological levels, they can be
cytotoxic, genotoxic, and proinflammatory, contributing to
the development of mucosal inflammation and
carcinogenesis.
There is increasing evidence that the reach of gut mi-
crobes extends beyond the intestine, affecting systemic
processes, such as metabolism and organ functions of brain,
cardiovascular system, liver, and others. Several metab-
olomic studies have identified hundreds of compounds in
blood that are specifically derived or dependent on the
presence of gut microbes.12 These findings have enlarged
our thinking about the impact of the gut microbiome,
particularly in influencing developmental processes and in
the physiological regulation of a vast array of tissue and cell
functions in the body.The role of gut dybiosis in causing and
sustaining disease states
The development of gut dysbiosis can set into play pro-
cesses that activate the host immune and inflammation
response, disturb intestinal homeostasis, and cause meta-
bolic abnormalities. As an example, many microbes are
selected by an inflammatory milieu because of their ability
to survive the hostile inflammatory milieu, in contrast to
many commensal microorganisms that cannot tolerate this
type of harsh environment. In turn, it is to their benefit to
maintain the inflammatory process to prevent the return of
competing commensal microorganisms, i.e. creating a vi-
cious cycle that leads to chronic disease. Their production
of pathogen-associated molecular patterns (PAMPs) that
include agents like flagellin, peptidoglycans, and lipopoly-
saccharide (LPS), further fuels the inflammatory process and
contribute to the extent, severity, and duration of mucosal
injury. Inflammation-induced intestinal barrier dysfunction
and frank ulceration can also promote systemic entry of
PAMPs that can affect many distant organs. For example,
increased LPS translocation, has been proposed as driver of
inflammation associated with obesity-related metabolic
disorders13 and type 2 diabetes.13,14 LPS, when subcutane-
ously infused into mice fed a normal diet, can also induce
chronic inflammation that promotes the development of
obesity and conditions of insulin resistance.14
Fei et al in fact demonstrated a causal relationship be-
tween endotoxin producers in the gut and obesity/insulin
resistance outcomes, which can be tracked by changes in
gut permeability, serum endotoxin, and inflammatory
biomarkers.15
Dysbiosis associated with various disorders can also be
characterized by lower community diversity. Resulting al-
terations in both structural (membership) and functionalprofiles of the gut microbiota in these circumstances are
believed to be major contributors to the etiopathogenesis
of complex immune, infectious, metabolic, and cancerous
disorders, including inflammatory bowel disease (IBD),16
neonatal necrotizing enterocolitis,11,12 gastrointestinal
(GI) cancers, asthma,17 allergy, and infectious diseases.
Even in organs that used to be considered sterile, such as
esophagus and lungs, microbiota have been found that may
contribute to the pathogenesis and progression of dis-
ease.13,14 Other studies have also demonstrated wide-
spread systemic effects of the gut microbiome determine
various physiological states, such as cardiac size, hepatic
gene expression, central nervous system function, and
behavioral patterns.18 Thus, gut dysbiosis can disrupt host-
microbe homeostasis and cause and/or contribute to many
human diseases beyond the digestive system.19
Alterations of the gut microbiota have been associated
with host metabolic disorders, including metabolic syn-
drome, type 2 diabetes, and obesity. One study demon-
strated that richness of the gut microbiome correlated with
certain metabolic markers.16 Akkermansia muciniphila, a
mucin-degrading microbe that resides in the mucus layer,
has been reported to prevent high-fat diet-induced meta-
bolic disorders, including fat-mass gain, metabolic endo-
toxemia, adipose tissue inflammation, and insulin
resistance.17 These effects appeared to be mediated by
enhanced intestinal levels of endocannabinoids that control
inflammation, the gut barrier, and gut peptide secretion.
The results provide a rationale for the development of a
treatment that uses this human mucus colonizer for the
prevention or treatment of obesity and its associated
metabolic disorders. Two recent reviews have explored the
microbiota in relation to metabolic phenotype and disease
risk.18,19
In other recent studies by Hazen’s group, the gut
microbiota have been shown to promote atherosclerosis
through metabolism of dietary carnitine and phosphatidyl-
choline.20,21 Both are sources of dietary choline which is
positively correlated with Bacteroides that is often associ-
ated with a Western diets. Choline is metabolized gut
microbiota to trimethylamine which further undergoes he-
patic metabolism to form trimethylamine oxide, the active
agent that promotes atherosclerosis through its proin-
flammatory properties.20
The gut microbiota also appears to affect the central
nervous system. A recent study showed that the gut
microbiota modulate behavioral and physiological abnor-
malities associated with neurodevelopmental disorders,
using a mouse model of autism spectrum disorder (ASD).21
Another study demonstrated that the leakiness of the in-
testine appears to be important in the development of
Parkinson’s disease,22 promoting systemic exposure to in-
testinal bacteria and their toxins. Finally, the gastrointes-
tinal tract is sensitive to stress and stress mediators,
including catecholamines. Irritable bowel syndrome (IBS) is
a common disorder through the gutebrain axis that might
be triggered by gut bacterial imbalance.23 The brainegut
axis allows bidirectional communication between the cen-
tral nervous system and the enteric nervous system, linking
emotional and cognitive centers of the brain with intestinal
functions.23 An association between dysbiosis and stress
and depressive disorder has also been proposed.22,24
Gut microbiota and human diseases 135In summary, host-microbe interactions can have health
and disease promoting effects in the gut and also in distal
organs (Fig. 1). The effects can be mediated by a plethora
of microbe-derived effector molecules that include me-
tabolites (SBA, SCFA), immune and inflammatory modula-
tors PAMPs, MAMPs (microbe-associated molecular
pattern), and secreted small natural products. Perturba-
tions of physiological host-microbe interactions can have
significant consequences to immune and metabolic ho-
meostasis at both the local and systemic level. The new
“steady-state” created by these events can become chronic
and difficult to break because of self-reinforcing host and
microbial processes that are set into play.Reshaping the gut microbiota to restore host-
microbial balance
The therapies for many disorders that have a microbial
component in their pathogenesis are mostly focused on the
host side (infectious diseases being the exception). Now, a
lot of thought is being given to manipulating the microbial
side of the equation to restore host-microbial balance.
There are various approaches to shape the gut microbiota,
including personalized probiotic, prebiotics (fiber),
vitamin/mineral supplementation, dietary, fecal micro-
biota transplantation (FMT), and/or the use of antibiotics.
Prebiotics largely comprise a group of carbohydrates that
cannot be degraded by the host but can otherwise promote
the growth, fitness and functional properties of beneficial
bacteria. Probiotics are live microbes that bestow the host
with health advantages, whether it is anti-inflammatory,
immunomodulatory, or trophic to the gut mucosa. They
may also provide benefit in digestion and absorption ofFigure 1 Host-bacterial interactions that could potentially med
distant organs. Gut microbiota influences amino acid bioavailabili
associated with dysfunction of intestinal barriers and enhances proi
factors could potentially influence pathogenesis and progression omany dietary nutrients and minerals. Because prebiotics
and probiotics differ in their properties and mechanisms of
action, their efficacy for treating many disorders is often
unpredictable. Patients take these agents empirically and
physician who prescribe them do so without consideration
of patient factors, the nature of the disease, and clear
endpoints. In addition, these agents are marketed as
nutraceuticals and, as such, are not subject to quality
control or proof of efficacy. Finally, the notion that these
agents can reshape the endogenous gut microbiome in a
consistent and predictable way is probably untenable. The
gut microbiota in most conditions has a substantial degree
of resilience that would preclude fitness and colonization
by non-indigenous probiotic microbes.
FMT is currently receiving a great deal of attention,
having the theoretical advantage of being a diverse mi-
crobial community preselected under conditions of health.
FMT has been found to be relatively safe and effective for
the treatment of refractory C. difficile infection.25 It is also
being considered the treatment of IBD, but these studies
are currently under FDA review. Issues regarding safety and
standardization of FMT have to be considered, particularly
since many of these patients may be immunocompromised.
We feel that FMT is not likely to be effective in moderate or
severe cases of IBD in absence of other therapies directed
against the host inflammatory and immune dysregulation.
Even then, the question remains how long the membership,
diversity, and function of the transferred microbiota can be
sustained under different set of conditions presented by
the new host’s genetic, environmental, and physiological
factors.
Several clinical and experimental studies have shown
that diet is one of the most consistent and predictable ways
of reshaping the gut microbiome. As shown by David,iate the gut microbiota human diseases in local intestine and
ty, is a source of metabolites (SBA, SCFA, PAMPs). Dysbiosis is
nflammatory cytokines (TNF-a, IFN-g, IL-1b, and IL-8). All these
f human diseases.
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microbial composition and function in healthy human sub-
jects. Shifts in microbial assemblage induced by diet can
have consequences for intestinal health, as was demon-
strated in a study of genetically susceptible IL-10 deficient
mice fed a diet rich in saturated milk fat. This diet pro-
moted a bloom of sulfite reducing Proteobacteria (Bilophila
wadsworthia), which increased the incidence and severity
of spontaneous colitis in these animals.27 Long-term pat-
terns of dietary consumption are associated with develop-
ment of specific enterotypes that can have consequences
for host immune function and disease risk. A recent study,
for example, demonstrated that restricting life-long food
intake by 30 per cent below what is needed to maintain
body weight in mice can significantly change the composi-
tion of the gut microbiota.28 This calorie restricted diet
promoted beneficial bacteria, such as Lactobacillus, and
reduced harmful bacteria. Another examples is that of
vitamin/mineral supplementation used for prevention and
treatment of diseases. Vitamin D and its receptor VDR were
shown to mitigate the dysbiosis associated with intestinal
inflammation,29 possibly by restoring immune homeostasis,
but also by direct effects on the gut microbiota.
In summary, targeting the gut microbiota is a promising
strategy for the prevention and treatment of human dis-
eases believed to be affected by the development of dys-
biosis. Restoring the healthy host-microbial interactions by
personalized prebiotics/probotics, FMT, and dietary may be
useful in achieving better clinical outcomes (Fig. 2).Figure 2 Targeting the gut microbiota in prevention and treatm
drates fermented in gut that selectively stimulate the growth and/
health benefits on the host. Probiotics are live microorganisms, w
benefit on the host. Personalized dietary and fecal microbiota trans
prevent or treat diseases through restoring healthy host-bacterialChallenges in the field
The study of the gut microbiome has advanced rapidly with
new developments in technology (both cultivation-
dependent and -independent) and bioinformatic tools for
assessing community structure, function, and potential in-
terrelationships among represented microorganisms. As a
direct results, we’ve come to realize that the gut micro-
biome can be quite heterogeneious among different pop-
ulations, influenced by changes in external factors (e.g.
environmental and dietary cues), states of health, and
intermicrobial and host assembly rules. An enormous
amount of data has been generated by the Human Micro-
biome Project and other consortiums, but most of this in-
formation remains descriptive and inferential, limited in
many cases by the lack of supporting experimental and
clinical data, incomplete development and vetting of
‘omic’ technologies, and still evolving bioinformatics plat-
forms for analyzing and integrating large datasets. These
data potentially represent a treasure trove of information,
not only for studies of bacteria, but also other microbes
including viruses, fungi and Archea. However, many formi-
dable challenges impede efforts to move the field forward.
Waiting for new technologies and bioinformatics tools
represents only part of the solution. Understanding how
these data relate to human physiology and disease will
require a closer partnership between the clinical and basic
sciences so that information is no longer viewed out of
context of clinical metadata and outcomes.ent of human diseases. Prebiotics are non-digestible carbohy-
or activity of a limited number of bacteria and thereby, confer
hich, when administered in adequate amount, confer a health
plantation (FMT)/of healthy donor feces to patients are used to
interactions.
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Despite rapid advances in technology and analysis of large
datasets, our ability to study the functional profiles of gut
microbiota and their impact on host remains a major chal-
lenge. Taxonomic information provided by the study of 16S
rRNA gene sets does not provide much information of com-
munity function, although attempts have been made by
using reference genomes of highly representedmicrobiota to
infer function.27 This approach remains unproven, largely
because the genome inventories of microbial functional
genes are still limited and incompletely curated. Thismay be
helped by new methodologies in cultivation of single strains
that may either be poorly represented in the gut microbiota
or difficult to grow.30 These approaches will lead to the
development of more complete microbial reference ge-
nomes. Even then, the conclusionsmade frombioinformatics
analyses has to be vetted by experimental and clinical
studies to determine if these approaches are meritorious.
Shotgun sequencing of sample DNA to obtain metagenomic
profiles is another approach to gain insights into community
function. Again, the interpretation of data is limited by
incomplete functional gene inventories, the fact that these
data may not reflect true gene expression, and biases
introduced by small sample biomass requiring gene amplifi-
cation and host DNA contamination. Metatranscriptomes in
theory provide a much more useful measure of gut microbial
community function, but, even then, this approach currently
requires fairly substantial sample biomass (restricting
studies to mostly luminal samples) because yield is
compromised by attempts to remove structural RNA to
enrich for mRNA. The interpretation of these data, as with
metagenomes, is further limited by the incomplete in-
ventories of microbial functional genes. Combining meta-
genomic andmetatranscriptome information, however, may
provide greater confidence and ability to interpret this col-
lective information, by confirming and potentially identi-
fying the origin of encoded transcripts.
One solution to the vexing problem of assessing microbial
function may come from new developments in ‘omic’
technologies and other functional assays. Significant ad-
vances have been made in proteomics, lipidomics, and
metabolomics that have increased the value of information
as well as cost for performing the analysis. For studies of the
gut microbiome, these approaches are still under develop-
ment and will require some form of experimental vetting to
substantiate their informational value, but they provide
promise because they are more direct measures of microbial
function. Other measures of microbial community function
are also under development, including candidate gene
analysis (e.g. Butyrate transferase and butyrate kinase, dsrA
and Biolog profiling) which provides an affordable, reli-
able, and informative metabolic signature of microbial
samples. As will be mentioned below, the data from these
types of studies will be particularly useful when viewed in
the context of clinical and experimental information. In line
with this, the second phase of the NIH Human Microbiome
Project (HMP 2), large databases, computational systems to
rapidly analyze and integrate data sets, and methodologies
for functional profiling of human microbiomes are being
developed for eventual use by end users.Clinical challenges
The idiom “garbage in, garbage out” is highly relevant to
the study the human gut microbiomes, particularly with
regard to the inattention to study design, clinical context,
and the type, acquisition, and processing of clinical sam-
ples. Most studies, particularly relating to IBD, have been
cross-sectional and without recognition that the study
populations are heterogeneous and that chronic diseases
often have a transitional natural history. IBD, for instance,
has traditionally been thought of as being two diseases,
Crohn’s Disease27 and ulcerative colitis (UC). In actuality,
these designations are clinical phenotypes based on clinical
presentation and histopathology. Over 160 genetic poly-
morphisms have now been identified through genome-wide
association studies that are associated with increased risk
for IBD, many shared between CD and UC. These data
indicate that IBD are many diseases having different etio-
pathogenic mechanisms. Other confounding factors muddy
the analysis of the gut microbiome in IBD. Most studies are
conducted after the onset of colitis when the immune and
inflammatory processes set into play can independently
create dysbiosis that negatively selects against commensal
microbes in favor of microorganisms that can survive the
harsh conditions of chronic inflammation. Whether the
observed dysbiosis is causative cannot be determined. In
addition, the confounding effects of medications (antibi-
otics, immunosuppressive agents), changes in diet and daily
lifestyle, and introduction of other environmental factors
(hospital settings) are usually not taken into consideration.
Chronic complex immune disorders like IBD are also tran-
sitional diseases, i.e. the initiating disease processes are
often quite different from those that present later in the
course of disease. For example, the development of mal-
digestion and malabsorption in CD at later stages of dis-
ease, caused by inflammation, anatomic alterations (e.g.
fistula, stenosis), and surgery, can dramatically affect the
composition and function of the gut microbiota. Conse-
quently, cross-sectional studies collecting samples indis-
criminately and failing to recognize these issues are
unlikely to yield meaningful information that would help to
understand cause-effect relationships or be translatable to
the prevention or treatment of IBD.
Almost all human microbiome studies of the GI tract are
based on the collection of stool samples, which can
potentially be limiting and misleading. First, the gut
microbiota are not uniformly distributed throughout the GI
tract, but exhibit regional heterogeneity. Their assemblage
in these areas is determined by ambient conditions and
available nutrients that are provided by their host as well as
partnering microbes. It is also known that the mucosa-
associated microbiota are quite distinct from those that are
found in the lumen, the former being more stable and
particularly adept in living with the host. Because both UC
and CD are anatomically distinct diseases, local factors,
especially gut microbes, are likely to play a key role in their
pathogenesis. CD can involve any part of the GI tract,
typically starting as a discrete ulceration surrounded by
normal mucosa, and eventually penetrating into and
sometimes through the bowel wall. UC, on the other hand,
only involves the colon, always starts in the rectum, and, in
138 J. Sun, E.B. Changmost cases, proceeds proximally as a contiguous front of
inflammation. Based on these considerations, stool collec-
tion as the sole means to assess the gut microbiota in IBD
can be inadequate. Finally, there is currently little stan-
dardization in the way samples are collected and processed
(e.g. brush, biopsy, how to store samples, optimization of
extract techniques, etc). All these nuances are likely to
affect the results and analysis, making it difficult to
compare results to identify true relationships.Overcoming the challenges and moving
forward
How can we resolve these issues? First, we should be more
circumspect about how to design our studies, collect sam-
ples, and analyze data. Upto now, most studies have been
technologically driven. As a result, a lot of data has been
generated and analyzed in isolation of other metadata.
Quality has been sacrificed for quantity and, in the end, the
studies have ended up with unsubstantiated associations
and questionable conclusions. Ideally, studies aimed at
identifying potential causal relationships should be per-
formed prospectively, using each subject as their own
control and collecting critical information before the onset
of disease to determine how they ultimately related to
clinical outcomes. For complex immune disorders, this is
difficult largely because subjects at risk who eventual
develop the disease cannot be easily identified. Neverthe-
less, there are a few conditions where this is feasible. In
Type I diabetes, “pre-diabetic” subjects can now be iden-
tified from whom, stool samples for microbiota analysis are
being collected prospectively.31,32 In IBD, studies of UC
patients who undergo total colectomy with Ileal pouch anal
anastomosis (IPAA) are being followed prospectively to
determine if changes in gut microbiota and/or host
response (e.g. transcriptomes, cytokine profiles) to predict
who will develop an inflammatory condition called pou-
chitis.33 Non-UC patients (e.g. those with familial adeno-
matous polyposis) undergoing the same surgical procedure
rarely develop this condition, suggesting this condition is a
recapitulation of some of the pathogenic processes that
originally caused the UC. IPAA-UC patients are also ideal
subjects for study because they are generally no longer on
medication, can be serially sampled endoscopically, and
over half will develop pouchitis within 12e15 months.
Therefore, the incidence and time course of disease make
if feasible to collect and analyze corresponding datasets to
potentially understand the factors that lead to pouchitis
which, in turn, could provide insights into the fundamental
cause of UC.
The identification of more homogeneous subsets of
subjects is essential for identifying key associations be-
tween gut microbiota and clinical outcomes. In this regard,
many groups have focused on twin studies where variations
in genetics can be minimized.34 Similarly, studies of more
homogeneous patient populations (Amish, Hutterites, Ash-
kenazum, African) have been increased the yield and
impact of these types of studies where, in addition to
common ancestral genetic backgrounds, factors such as
environment, diet, life style, etc can be more easily
controlled and studied. Even in a heterogeneous group,such as IBD patients, information collected longitudinally
and carefully analyzed in the context of clinical stage and
other metadata can provide important insights into the role
of gut microbes in disease remission or relapse.
Despite our best efforts to design the most optimal
human subjects based study, establishing true causality and
defining disease pathogenesis remain difficult. Humans are
so individual and the ability to rigorously control clinical
parameters and variables is often beyond what is ethically
and technically possible. The utilization of experimental
approaches and models is therefore an essential counter-
part to human-based research. For the study of host-
microbe interactions, in vitro and in vivo models have
been extremely useful in defining important relationship
that could not otherwise be achieved through clinical
studies. These types of studies can serve the additional
purpose of vetting many of the modeling and bioinformatic
approaches used by investigators to draw conclusions from
large clinical datasets. One of the limitations of the first
phase of the Human Microbiome Project was that studies
focused solely on the human microbiota. As a consequence,
opportunity was lost in gaining insights of evaluating the
significance of findings in the context of host responses and
experimental models where study parameters and genetics
can be carefully controlled. Having said this, the caveat to
the experimental approach that they don’t always reca-
pitulate the biology and pathobiology of humans. Thus,
studies of gut microbiota should be multi-pronged and the
approach should be iterative between humans and experi-
mental systems. Standardizing approaches for sample
acquisition and processing are also needed.
Finally, many of us have come to realize that reaching
for the high hanging fruit where discovery lies requires a
multi-disciplinary team effort, involving basic, trans-
lational, and clinical investigators who each bring some-
thing to the table. The next phase of research investigation
of the gut microbiome should be guided by specific bio-
logical questions relevant to the clinical aspects and natu-
ral history of the disease, utilizing the full spectrum of
‘omic’ technologies, bioinformatic analysis, and experi-
mental models.
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